1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Purpose. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications that propose to develop novel pharmacologic agents for brain research related to mental disorders, including research aimed at discovering new drugs for these disorders. In addition, this FOA solicits SBIR grant applications that propose to take existing, promising compounds through the next step of drug discovery and development. Finally, this FOA also encourages SBIR grant applications designed to study the effectiveness of novel interventions. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Budget and Project Period. Phase I awards normally may not exceed $100,000 total for a period normally not to exceed 6 months. Phase II awards normally may not exceed $750,000 total for a period normally not to exceed 2 years. However, for this funding opportunity, budgets up to $350,000 total costs per year and time periods up to two years for Phase I may be requested. Budgets up to $600,000 total costs per year and up to three years may be requested for Phase II. Eligible Institutions/Organizations: Only United States SBCs are eligible to receive SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. Eligible Project Directors/Principal Investigators: Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. On an SBIR application, the PD/PI must have his/her primary employment (more than 50%) with the SBC at the time of award and for the duration of the project. Number of Applications: Applicant SBCs may submit more than one application, provided each application is scientifically distinct. Resubmissions: Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). Number of PDs/PIs. More than one PD/PI, or multiple PDs/PIs, may be designated on the application.
Funding Opportunity Number: PA-08-142. Assistance Listing: 93.242. Funding Instrument: G. Category: HL.
Get alerted about grants like this
Save a search for “National Institutes of Health” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: Small businesses. Other Eligible Applicants include the following: 1. Organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; 2. In the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there can be no more than 49 percent participation by business entities in the joint venture; 3. At least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States, or it must be a for-profit business concern that is at least 51% owned and controlled by another for-profit business concern that is at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States -- (except in the case of a joint venture); 4. Has, including its affiliates, not more than 500 employees and meets the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns, other than investment companies licensed, or state development companies qualifying under the Small Business Investment Act of 1958, 15 U.S.C. 661, et seq., are affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is May 7, 2011. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Purpose. This FOA issued by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS) solicits Research Project Grant (R01) applications from institutions/organizations that propose to conduct basic and translational research into the neurobiology of pain in sickle cell disease. Applications that promote multidisciplinary collaboration are strongly encouraged. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism. Funds Available and Anticipated Number of Awards. NHLBI intends to commit up to $6.0 million (total costs) over four years and NINDS intends to commit up to $1.4 million (total costs) over four years.The NHLBI and NINDS anticipate that they will award up to $1.85 million in FY 2009 to fund four applications in response to this FOA.Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Funding Opportunity Number: RFA-HL-09-008. Assistance Listing: 93.839,93.853. Funding Instrument: G. Category: HL. Award Amount: Up to $300K per award.
Purpose.This Funding Opportunity Announcement (FOA), issued by the National Institute of Mental Health (NIMH), solicits Exploratory/Developmental Phased Innovation (R21/R33) grant applications from institutions or organizations that propose to generate and characterize induced pluripotent stem (iPS) cells from human control and/or patient populations with cognitive, affective, social, sleep and developmental brain disorders. This can, but does not need to, include disorders in which a genetic linkage has already been inferred. Applications that combine expertise in stem cell biology, cortical development and the clinical study or treatment of mental disorders are strongly encouraged. Responsive applications will place an emphasis on appropriate validation of iPS cells and their derivatives, evaluating the hetero/homogeneity of any cell populations to be screened and use of cellular assays relevant to brain function and mental disorders. Studies involving the acquisition of tissue from new subjects should include provisions to archive and distribute non-induced (e.g., primary) cells. Since studies likely require several areas of expertise, applicants are encouraged to include multiple PIs on the application. Funding Opportunity Number: RFA-MH-09-130. Assistance Listing: 93.242. Funding Instrument: G. Category: HL. Award Amount: Up to $200K per award.
Purpose. Under this Funding Opportunity Announcement (FOA), the National Institute on Alcohol Abuse and Alcoholism requests Research Project Grant (R01) applications: 1) to test innovative single and combined pharmacologic therapies for alcohol use disorders in HIV+ populations for the purpose of improving adherence to antiretroviral medications, reducing the rate of viral mutation and toxicity related to alcohol-ARV interactions, and reducing sexual risk-taking; and 2) to assess the potential usefulness of medications for alcohol use disorders in preventing secondary HIV infections in targeted high risk populations of gay men and minority women. Mechanism of Support. This FOA will utilize the R01 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-AA-09-008, that solicits applications under the expanded R03 grant mechanism to do initial studies of the safety and feasibility of pharmacotherapies for alcohol use disorders in HIV-infected populations. Funds Available and Anticipated Number of Awards. A total of $3.0 M will be awarded and 4-6 awards are anticipated. Funding Opportunity Number: RFA-AA-09-007. Assistance Listing: 93.273. Funding Instrument: G. Category: HL. Award Amount: $3M total program funding.